✦ LIBER ✦

A Phase I study of men-10755 in patients with a solid tumor as a shorti.v. infusion given once every 3 weeks

✍ Scribed by Roelvink, M.; Aamdal, S.; Dombernowsky, P.; Wanders, J.; Peters, S.; Bortini, S.; Crea, A.; Animati, A.; Hanauske, A.-R.

Book ID: 122432861
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 136 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(99)81581-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I study of raltitrexed and pacli

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

✍ Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Ma 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of a

Phase I dose-escalating study of ES-285

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

✍ C. Massard, R. Salazar, J. P. Armand, M. Majem, E. Deutsch, M. García, A. Oaknin 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 591 KB

A phase I pharmacokinetic study of PM001

A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors

✍ J. Capdevila, S. Clive, E. Casado, C. Michie… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 274 KB

A phase I and pharmacokinetic study of R

A phase I and pharmacokinetic study of RP 60475F administered as a one hour IV infusion every 3 weeks in solid tumors

✍ Abigerges, D; Catimel, G; Klink Alakl, M; Bruno, R; Chabot, G; Ardiet, C; Nieman 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 143 KB

570 Phase 1 study of XMT-1001, a novel w

570 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an IV infusion every 3 weeks to patients with advanced solid tumors

✍ R.J. Fram; L.E. Garbo; G.J. Weiss; D. Shkolny; A.V. Yurkovetskiy; C. Bethune; R. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

A phase 1 study of OSI-211 given as an i

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

✍ K. Gelmon; H. Hirte; B. Fisher; W. Walsh; M. Ptaszynski; M. Hamilton; N. Onetto; 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 283 KB